RU2100030C1 - Водная суспензия, содержащая микрокристаллы фармакологически активного водонерастворимого лекарственного вещества, покрытые мембранообразующим липидом (варианты), и лиофилизированный препарат водной суспензии - Google Patents

Водная суспензия, содержащая микрокристаллы фармакологически активного водонерастворимого лекарственного вещества, покрытые мембранообразующим липидом (варианты), и лиофилизированный препарат водной суспензии Download PDF

Info

Publication number: RU2100030C1
Authority: RU; Russia
Prior art keywords: drug; water; microcrystals; lipid; coated
Prior art date: 1990-04-26

Application number

RU9292016352A

Other languages

English (en)

Russian (ru)

Other versions

RU92016352A (ru

Inventor

Х.Хейнес Дункан

Original Assignee

Фарма-Логик, Инк.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-04-26

Filing date

1991-04-23

Publication date

1997-12-27

1991-04-23 Application filed by Фарма-Логик, Инк. filed Critical Фарма-Логик, Инк.

1995-02-10 Publication of RU92016352A publication Critical patent/RU92016352A/ru

1997-12-27 Application granted granted Critical

1997-12-27 Publication of RU2100030C1 publication Critical patent/RU2100030C1/ru

Links

239000013081 microcrystal Substances 0.000 title claims abstract description 121
150000002632 lipids Chemical class 0.000 title claims abstract description 54
239000007900 aqueous suspension Substances 0.000 title claims abstract description 15
238000002360 preparation method Methods 0.000 title claims description 58
239000012907 medicinal substance Substances 0.000 title 1
239000003814 drug Substances 0.000 claims abstract description 223
229940079593 drug Drugs 0.000 claims abstract description 215
150000003904 phospholipids Chemical class 0.000 claims abstract description 98
239000000725 suspension Substances 0.000 claims abstract description 45
239000000126 substance Substances 0.000 claims abstract description 17
239000007787 solid Substances 0.000 claims abstract description 13
238000002347 injection Methods 0.000 claims description 82
239000007924 injection Substances 0.000 claims description 82
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 76
238000000576 coating method Methods 0.000 claims description 53
239000011248 coating agent Substances 0.000 claims description 48
239000012528 membrane Substances 0.000 claims description 35
239000008186 active pharmaceutical agent Substances 0.000 claims description 15
229940088679 drug related substance Drugs 0.000 claims description 15
239000012895 dilution Substances 0.000 claims description 14
238000010790 dilution Methods 0.000 claims description 14
DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims description 10
239000012188 paraffin wax Substances 0.000 claims description 9
239000011859 microparticle Substances 0.000 claims description 8
229940056211 paraffin Drugs 0.000 claims description 8
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 7
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 6
HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 claims description 6
230000008018 melting Effects 0.000 claims description 5
238000002844 melting Methods 0.000 claims description 5
235000019271 petrolatum Nutrition 0.000 claims description 4
239000004264 Petrolatum Substances 0.000 claims description 3
229940082500 cetostearyl alcohol Drugs 0.000 claims description 3
229960000541 cetyl alcohol Drugs 0.000 claims description 3
239000003651 drinking water Substances 0.000 claims description 3
235000020188 drinking water Nutrition 0.000 claims description 3
238000007912 intraperitoneal administration Methods 0.000 claims description 3
230000003902 lesion Effects 0.000 claims description 3
229940043348 myristyl alcohol Drugs 0.000 claims description 3
229940066842 petrolatum Drugs 0.000 claims description 3
OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims description 3
230000000699 topical effect Effects 0.000 claims description 3
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims description 2
229940093471 ethyl oleate Drugs 0.000 claims description 2
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims description 2
230000002601 intratumoral effect Effects 0.000 claims description 2
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 2
229940012831 stearyl alcohol Drugs 0.000 claims description 2
230000000694 effects Effects 0.000 abstract description 5
239000000787 lecithin Substances 0.000 description 108
235000010445 lecithin Nutrition 0.000 description 108
229940067606 lecithin Drugs 0.000 description 106
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 105
IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 64
239000004100 Oxytetracycline Substances 0.000 description 61
229960000625 oxytetracycline Drugs 0.000 description 61
235000019366 oxytetracycline Nutrition 0.000 description 61
IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 61
239000002245 particle Substances 0.000 description 59
239000000203 mixture Substances 0.000 description 47
210000001519 tissue Anatomy 0.000 description 42
238000000034 method Methods 0.000 description 38
239000000243 solution Substances 0.000 description 33
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 30
239000013078 crystal Substances 0.000 description 30
241000700159 Rattus Species 0.000 description 27
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 26
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 26
210000004369 blood Anatomy 0.000 description 26
239000008280 blood Substances 0.000 description 26
239000008103 glucose Substances 0.000 description 26
239000010410 layer Substances 0.000 description 24
239000000463 material Substances 0.000 description 23
210000003205 muscle Anatomy 0.000 description 23
206010002091 Anaesthesia Diseases 0.000 description 22
230000037005 anaesthesia Effects 0.000 description 22
238000010255 intramuscular injection Methods 0.000 description 21
239000007927 intramuscular injection Substances 0.000 description 21
239000003921 oil Substances 0.000 description 21
235000019198 oils Nutrition 0.000 description 21
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 20
238000009472 formulation Methods 0.000 description 18
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
241001465754 Metazoa Species 0.000 description 17
238000004090 dissolution Methods 0.000 description 17
239000008344 egg yolk phospholipid Substances 0.000 description 16
238000002474 experimental method Methods 0.000 description 16
230000015572 biosynthetic process Effects 0.000 description 15
230000008569 process Effects 0.000 description 15
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 14
238000012545 processing Methods 0.000 description 14
239000002904 solvent Substances 0.000 description 14
229960002372 tetracaine Drugs 0.000 description 14
GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 14
229960003276 erythromycin Drugs 0.000 description 13
230000002093 peripheral effect Effects 0.000 description 13
238000011282 treatment Methods 0.000 description 13
239000007788 liquid Substances 0.000 description 12
239000012071 phase Substances 0.000 description 12
235000011187 glycerol Nutrition 0.000 description 11
230000007794 irritation Effects 0.000 description 11
230000007774 longterm Effects 0.000 description 11
239000003960 organic solvent Substances 0.000 description 11
239000000047 product Substances 0.000 description 11
238000003860 storage Methods 0.000 description 11
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 10
238000004458 analytical method Methods 0.000 description 10
239000011521 glass Substances 0.000 description 10
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 10
239000007983 Tris buffer Substances 0.000 description 9
239000003795 chemical substances by application Substances 0.000 description 9
235000014113 dietary fatty acids Nutrition 0.000 description 9
239000000975 dye Substances 0.000 description 9
239000000194 fatty acid Substances 0.000 description 9
229930195729 fatty acid Natural products 0.000 description 9
150000004665 fatty acids Chemical class 0.000 description 9
125000005843 halogen group Chemical group 0.000 description 9
238000001990 intravenous administration Methods 0.000 description 9
238000004062 sedimentation Methods 0.000 description 9
238000012360 testing method Methods 0.000 description 9
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 9
239000001993 wax Substances 0.000 description 9
VXTGHWHFYNYFFV-UHFFFAOYSA-N albendazole S-oxide Chemical compound CCCS(=O)C1=CC=C2NC(NC(=O)OC)=NC2=C1 VXTGHWHFYNYFFV-UHFFFAOYSA-N 0.000 description 8
229950010075 albendazole sulfoxide Drugs 0.000 description 8
229960003305 alfaxalone Drugs 0.000 description 8
238000013459 approach Methods 0.000 description 8
230000008859 change Effects 0.000 description 8
238000010253 intravenous injection Methods 0.000 description 8
239000002502 liposome Substances 0.000 description 8
239000002736 nonionic surfactant Substances 0.000 description 8
239000002244 precipitate Substances 0.000 description 8
239000001044 red dye Substances 0.000 description 8
DUHUCHOQIDJXAT-OLVMNOGESA-N 3-hydroxy-(3-α,5-α)-Pregnane-11,20-dione Chemical compound C([C@@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1=O DUHUCHOQIDJXAT-OLVMNOGESA-N 0.000 description 7
230000002776 aggregation Effects 0.000 description 7
238000004220 aggregation Methods 0.000 description 7
239000012736 aqueous medium Substances 0.000 description 7
230000006378 damage Effects 0.000 description 7
229960000905 indomethacin Drugs 0.000 description 7
230000036407 pain Effects 0.000 description 7
230000000144 pharmacologic effect Effects 0.000 description 7
239000000843 powder Substances 0.000 description 7
239000003755 preservative agent Substances 0.000 description 7
239000000523 sample Substances 0.000 description 7
230000005653 Brownian motion process Effects 0.000 description 6
HXHWSAZORRCQMX-UHFFFAOYSA-N albendazole Chemical compound CCCSC1=CC=C2NC(NC(=O)OC)=NC2=C1 HXHWSAZORRCQMX-UHFFFAOYSA-N 0.000 description 6
229960002669 albendazole Drugs 0.000 description 6
-1 alkyl cyanoacrylate Chemical compound 0.000 description 6
238000005537 brownian motion Methods 0.000 description 6
239000000872 buffer Substances 0.000 description 6
238000009826 distribution Methods 0.000 description 6
235000019441 ethanol Nutrition 0.000 description 6
210000002683 foot Anatomy 0.000 description 6
230000002209 hydrophobic effect Effects 0.000 description 6
230000003993 interaction Effects 0.000 description 6
238000007918 intramuscular administration Methods 0.000 description 6
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 6
239000002356 single layer Substances 0.000 description 6
PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 5
241000283690 Bos taurus Species 0.000 description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
229930003427 Vitamin E Natural products 0.000 description 5
239000012670 alkaline solution Substances 0.000 description 5
230000003444 anaesthetic effect Effects 0.000 description 5
239000007864 aqueous solution Substances 0.000 description 5
210000001367 artery Anatomy 0.000 description 5
238000001704 evaporation Methods 0.000 description 5
230000008020 evaporation Effects 0.000 description 5
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 5
229940071870 hydroiodic acid Drugs 0.000 description 5
210000002414 leg Anatomy 0.000 description 5
238000002483 medication Methods 0.000 description 5
239000002609 medium Substances 0.000 description 5
238000001556 precipitation Methods 0.000 description 5
150000003839 salts Chemical class 0.000 description 5
238000000527 sonication Methods 0.000 description 5
235000015112 vegetable and seed oil Nutrition 0.000 description 5
239000008158 vegetable oil Substances 0.000 description 5
235000019165 vitamin E Nutrition 0.000 description 5
229940046009 vitamin E Drugs 0.000 description 5
239000011709 vitamin E Substances 0.000 description 5
OZOMQRBLCMDCEG-CHHVJCJISA-N 1-[(z)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(O1)=CC=C1\C=N/N1C(=O)NC(=O)C1 OZOMQRBLCMDCEG-CHHVJCJISA-N 0.000 description 4
QHZLMUACJMDIAE-UHFFFAOYSA-N 1-monopalmitoylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)CO QHZLMUACJMDIAE-UHFFFAOYSA-N 0.000 description 4
RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 4
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 4
230000036592 analgesia Effects 0.000 description 4
238000011888 autopsy Methods 0.000 description 4
230000009286 beneficial effect Effects 0.000 description 4
239000011575 calcium Substances 0.000 description 4
229910052791 calcium Inorganic materials 0.000 description 4
244000309466 calf Species 0.000 description 4
239000001768 carboxy methyl cellulose Substances 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
229960001987 dantrolene Drugs 0.000 description 4
230000007423 decrease Effects 0.000 description 4
238000000605 extraction Methods 0.000 description 4
239000003925 fat Substances 0.000 description 4
150000002190 fatty acyls Chemical group 0.000 description 4
239000012634 fragment Substances 0.000 description 4
RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 4
238000000265 homogenisation Methods 0.000 description 4
230000005661 hydrophobic surface Effects 0.000 description 4
238000001361 intraarterial administration Methods 0.000 description 4
RFKMCNOHBTXSMU-UHFFFAOYSA-N methoxyflurane Chemical compound COC(F)(F)C(Cl)Cl RFKMCNOHBTXSMU-UHFFFAOYSA-N 0.000 description 4
229960002455 methoxyflurane Drugs 0.000 description 4
239000002480 mineral oil Substances 0.000 description 4
235000010446 mineral oil Nutrition 0.000 description 4
NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 4
230000009257 reactivity Effects 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
229920006395 saturated elastomer Polymers 0.000 description 4
230000035945 sensitivity Effects 0.000 description 4
239000004094 surface-active agent Substances 0.000 description 4
150000003626 triacylglycerols Chemical class 0.000 description 4
229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
229930186217 Glycolipid Natural products 0.000 description 3
102000003886 Glycoproteins Human genes 0.000 description 3
108090000288 Glycoproteins Proteins 0.000 description 3
206010022086 Injection site pain Diseases 0.000 description 3
206010039509 Scab Diseases 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
PPWHTZKZQNXVAE-UHFFFAOYSA-N Tetracaine hydrochloride Chemical compound Cl.CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 PPWHTZKZQNXVAE-UHFFFAOYSA-N 0.000 description 3
230000009471 action Effects 0.000 description 3
239000013543 active substance Substances 0.000 description 3
239000000427 antigen Substances 0.000 description 3
102000036639 antigens Human genes 0.000 description 3
108091007433 antigens Proteins 0.000 description 3
230000004888 barrier function Effects 0.000 description 3
OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 3
230000008901 benefit Effects 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
239000008112 carboxymethyl-cellulose Substances 0.000 description 3
239000000679 carrageenan Substances 0.000 description 3
235000010418 carrageenan Nutrition 0.000 description 3
229920001525 carrageenan Polymers 0.000 description 3
229940113118 carrageenan Drugs 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
210000000170 cell membrane Anatomy 0.000 description 3
239000003599 detergent Substances 0.000 description 3
239000012153 distilled water Substances 0.000 description 3
238000005194 fractionation Methods 0.000 description 3
238000004108 freeze drying Methods 0.000 description 3
238000002955 isolation Methods 0.000 description 3
230000033001 locomotion Effects 0.000 description 3
230000014759 maintenance of location Effects 0.000 description 3
230000000813 microbial effect Effects 0.000 description 3
230000007935 neutral effect Effects 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 3
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 3
229960003415 propylparaben Drugs 0.000 description 3
239000000344 soap Substances 0.000 description 3
238000010186 staining Methods 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
238000003756 stirring Methods 0.000 description 3
229960002494 tetracaine hydrochloride Drugs 0.000 description 3
210000003462 vein Anatomy 0.000 description 3
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 3
BOSAWIQFTJIYIS-UHFFFAOYSA-N 1,1,1-trichloro-2,2,2-trifluoroethane Chemical compound FC(F)(F)C(Cl)(Cl)Cl BOSAWIQFTJIYIS-UHFFFAOYSA-N 0.000 description 2
CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical group CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 2
JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
208000003443 Unconsciousness Diseases 0.000 description 2
206010047249 Venous thrombosis Diseases 0.000 description 2
241000212749 Zesius chrysomallus Species 0.000 description 2
ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 2
210000000683 abdominal cavity Anatomy 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
239000000654 additive Chemical group 0.000 description 2
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
230000000507 anthelmentic effect Effects 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
229960000686 benzalkonium chloride Drugs 0.000 description 2
SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
239000012267 brine Substances 0.000 description 2
244000309464 bull Species 0.000 description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
238000005056 compaction Methods 0.000 description 2
230000000536 complexating effect Effects 0.000 description 2
239000012141 concentrate Substances 0.000 description 2
230000008602 contraction Effects 0.000 description 2
238000013270 controlled release Methods 0.000 description 2
229960003290 cortisone acetate Drugs 0.000 description 2
239000006071 cream Substances 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
238000002845 discoloration Methods 0.000 description 2
ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
235000013601 eggs Nutrition 0.000 description 2
238000001506 fluorescence spectroscopy Methods 0.000 description 2
230000004927 fusion Effects 0.000 description 2
238000002695 general anesthesia Methods 0.000 description 2
238000000227 grinding Methods 0.000 description 2
125000001183 hydrocarbyl group Chemical group 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
229940025708 injectable product Drugs 0.000 description 2
229940102213 injectable suspension Drugs 0.000 description 2
239000003589 local anesthetic agent Substances 0.000 description 2
239000000693 micelle Substances 0.000 description 2
239000003094 microcapsule Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
229940074096 monoolein Drugs 0.000 description 2
229960003924 oxytetracycline dihydrate Drugs 0.000 description 2
238000003921 particle size analysis Methods 0.000 description 2
239000008188 pellet Substances 0.000 description 2
208000001297 phlebitis Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
150000003905 phosphatidylinositols Chemical class 0.000 description 2
239000002798 polar solvent Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
230000002335 preservative effect Effects 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
230000002685 pulmonary effect Effects 0.000 description 2
HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
238000001953 recrystallisation Methods 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
238000012552 review Methods 0.000 description 2
238000009738 saturating Methods 0.000 description 2
239000013049 sediment Substances 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
239000011343 solid material Substances 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
230000008961 swelling Effects 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
201000005060 thrombophlebitis Diseases 0.000 description 2
230000000451 tissue damage Effects 0.000 description 2
231100000827 tissue damage Toxicity 0.000 description 2
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
238000002255 vaccination Methods 0.000 description 2
238000005303 weighing Methods 0.000 description 2
ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
LZLVZIFMYXDKCN-QJWFYWCHSA-N 1,2-di-O-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC LZLVZIFMYXDKCN-QJWFYWCHSA-N 0.000 description 1
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
IJFVSSZAOYLHEE-UHFFFAOYSA-N 2,3-di(dodecanoyloxy)propyl 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCC IJFVSSZAOYLHEE-UHFFFAOYSA-N 0.000 description 1
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
GRWKNBPOGBTZMN-UHFFFAOYSA-N 2-benzyl-3-phenylpropane-1,2-diamine Chemical compound C=1C=CC=CC=1CC(N)(CN)CC1=CC=CC=C1 GRWKNBPOGBTZMN-UHFFFAOYSA-N 0.000 description 1
LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
241000517645 Abra Species 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
206010003497 Asphyxia Diseases 0.000 description 1
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
239000010755 BS 2869 Class G Substances 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
244000025254 Cannabis sativa Species 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
229920001651 Cyanoacrylate Polymers 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
208000005189 Embolism Diseases 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
206010018691 Granuloma Diseases 0.000 description 1
GUTXTARXLVFHDK-UHFFFAOYSA-N Haloperidol decanoate Chemical compound C1CC(OC(=O)CCCCCCCCC)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 GUTXTARXLVFHDK-UHFFFAOYSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
AXISYYRBXTVTFY-UHFFFAOYSA-N Isopropyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OC(C)C AXISYYRBXTVTFY-UHFFFAOYSA-N 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
206010024769 Local reaction Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
208000007101 Muscle Cramp Diseases 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
229910002651 NO3 Chemical group 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical group [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
241001494479 Pecora Species 0.000 description 1
108010020346 Polyglutamic Acid Proteins 0.000 description 1
108010039918 Polylysine Proteins 0.000 description 1
206010038687 Respiratory distress Diseases 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
208000005392 Spasm Diseases 0.000 description 1
241000519995 Stachys sylvatica Species 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
208000002847 Surgical Wound Diseases 0.000 description 1
BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
IUJDSEJGGMCXSG-UHFFFAOYSA-N Thiopental Chemical compound CCCC(C)C1(CC)C(=O)NC(=S)NC1=O IUJDSEJGGMCXSG-UHFFFAOYSA-N 0.000 description 1
208000001435 Thromboembolism Diseases 0.000 description 1
108010046377 Whey Proteins Proteins 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
150000003973 alkyl amines Chemical class 0.000 description 1
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
229960003942 amphotericin b Drugs 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
239000003098 androgen Substances 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
239000000921 anthelmintic agent Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940124599 anti-inflammatory drug Drugs 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000012062 aqueous buffer Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
239000012752 auxiliary agent Substances 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000011324 bead Substances 0.000 description 1
UKMSUNONTOPOIO-UHFFFAOYSA-M behenate Chemical compound CCCCCCCCCCCCCCCCCCCCCC([O-])=O UKMSUNONTOPOIO-UHFFFAOYSA-M 0.000 description 1
229940116224 behenate Drugs 0.000 description 1
JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
150000001649 bromium compounds Chemical group 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
229940067596 butylparaben Drugs 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
229960001777 castor oil Drugs 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
229960001231 choline Drugs 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
230000035602 clotting Effects 0.000 description 1
239000011247 coating layer Substances 0.000 description 1
230000009918 complex formation Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000010924 continuous production Methods 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
239000002178 crystalline material Substances 0.000 description 1
DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 1
230000006837 decompression Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
229960003529 diazepam Drugs 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
229910001873 dinitrogen Inorganic materials 0.000 description 1
FRKBLBQTSTUKOV-UHFFFAOYSA-N diphosphatidyl glycerol Natural products OP(O)(=O)OCC(OP(O)(O)=O)COP(O)(O)=O FRKBLBQTSTUKOV-UHFFFAOYSA-N 0.000 description 1
238000002224 dissection Methods 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
239000003640 drug residue Substances 0.000 description 1
229920001971 elastomer Polymers 0.000 description 1
238000001493 electron microscopy Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000005284 excitation Effects 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
238000002073 fluorescence micrograph Methods 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000003193 general anesthetic agent Substances 0.000 description 1
229960001731 gluceptate Drugs 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
150000002313 glycerolipids Chemical class 0.000 description 1
150000002314 glycerols Chemical class 0.000 description 1
230000005484 gravity Effects 0.000 description 1
229960005007 haloperidol decanoate Drugs 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
239000010460 hemp oil Substances 0.000 description 1
229920006158 high molecular weight polymer Polymers 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
210000000548 hind-foot Anatomy 0.000 description 1
XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
229910000043 hydrogen iodide Inorganic materials 0.000 description 1
230000005660 hydrophilic surface Effects 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
239000000408 hypertonic glucose solution Substances 0.000 description 1
239000000819 hypertonic solution Substances 0.000 description 1
229940021223 hypertonic solution Drugs 0.000 description 1
230000028993 immune response Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
UETZVSHORCDDTH-UHFFFAOYSA-N iron(2+);hexacyanide Chemical compound [Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] UETZVSHORCDDTH-UHFFFAOYSA-N 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
210000003127 knee Anatomy 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
208000030175 lameness Diseases 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
150000002634 lipophilic molecules Chemical class 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
238000011068 loading method Methods 0.000 description 1
238000002690 local anesthesia Methods 0.000 description 1
229960004391 lorazepam Drugs 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000000395 magnesium oxide Substances 0.000 description 1
CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000003550 marker Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000008384 membrane barrier Effects 0.000 description 1
230000002906 microbiologic effect Effects 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
229940042472 mineral oil Drugs 0.000 description 1
239000002395 mineralocorticoid Substances 0.000 description 1
239000003158 myorelaxant agent Substances 0.000 description 1
239000002105 nanoparticle Substances 0.000 description 1
229950006327 napsilate Drugs 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
SVMGVZLUIWGYPH-UHFFFAOYSA-N nitroscanate Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC1=CC=C(N=C=S)C=C1 SVMGVZLUIWGYPH-UHFFFAOYSA-N 0.000 description 1
229950009909 nitroscanate Drugs 0.000 description 1
239000012454 non-polar solvent Substances 0.000 description 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
231100000862 numbness Toxicity 0.000 description 1
229960000988 nystatin Drugs 0.000 description 1
VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
229940055577 oleyl alcohol Drugs 0.000 description 1
XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
238000010979 pH adjustment Methods 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
238000005192 partition Methods 0.000 description 1
235000019371 penicillin G benzathine Nutrition 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
230000035699 permeability Effects 0.000 description 1
239000000575 pesticide Substances 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
125000001095 phosphatidyl group Chemical group 0.000 description 1
230000010399 physical interaction Effects 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229940068918 polyethylene glycol 400 Drugs 0.000 description 1
229920002643 polyglutamic acid Polymers 0.000 description 1
229920000656 polylysine Polymers 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000013641 positive control Substances 0.000 description 1
244000144977 poultry Species 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
239000002510 pyrogen Substances 0.000 description 1
230000008707 rearrangement Effects 0.000 description 1
239000005871 repellent Substances 0.000 description 1
230000002940 repellent Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
XWGJFPHUCFXLBL-UHFFFAOYSA-M rongalite Chemical compound [Na+].OCS([O-])=O XWGJFPHUCFXLBL-UHFFFAOYSA-M 0.000 description 1
238000005070 sampling Methods 0.000 description 1
231100000241 scar Toxicity 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
230000001624 sedative effect Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000010008 shearing Methods 0.000 description 1
230000035939 shock Effects 0.000 description 1
238000004513 sizing Methods 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
239000002002 slurry Substances 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
238000007711 solidification Methods 0.000 description 1
230000008023 solidification Effects 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
239000008347 soybean phospholipid Substances 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
229940031439 squalene Drugs 0.000 description 1
TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
239000003270 steroid hormone Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
210000001179 synovial fluid Anatomy 0.000 description 1
239000008399 tap water Substances 0.000 description 1
235000020679 tap water Nutrition 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
229960003279 thiopental Drugs 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
229940072690 valium Drugs 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
230000002747 voluntary effect Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1
238000009736 wetting Methods 0.000 description 1
235000021119 whey protein Nutrition 0.000 description 1

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Microbiology (AREA)
Mycology (AREA)
Dispersion Chemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

RU9292016352A 1990-04-26 1991-04-23 Водная суспензия, содержащая микрокристаллы фармакологически активного водонерастворимого лекарственного вещества, покрытые мембранообразующим липидом (варианты), и лиофилизированный препарат водной суспензии RU2100030C1 (ru)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US514,012		1990-04-26
US514012		1990-04-26
US07/514,012 US5091188A (en)	1990-04-26	1990-04-26	Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
PCT/US1991/002804 WO1991016068A1 (en)	1990-04-26	1991-04-23	Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs

Publications (2)

Publication Number	Publication Date
RU92016352A RU92016352A (ru)	1995-02-10
RU2100030C1 true RU2100030C1 (ru)	1997-12-27

Family

ID=24045456

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
RU9292016352A RU2100030C1 (ru)	1990-04-26	1991-04-23	Водная суспензия, содержащая микрокристаллы фармакологически активного водонерастворимого лекарственного вещества, покрытые мембранообразующим липидом (варианты), и лиофилизированный препарат водной суспензии

Country Status (16)

Country	Link
US (2)	US5091188A (2)
EP (1)	EP0533690B1 (2)
JP (1)	JP3261129B2 (2)
KR (1)	KR0159114B1 (2)
AT (1)	ATE181234T1 (2)
AU (1)	AU7852891A (2)
CA (1)	CA2078990C (2)
DE (1)	DE69131349T2 (2)
DK (1)	DK0533690T3 (2)
ES (1)	ES2134776T3 (2)
GR (1)	GR3030825T3 (2)
MX (1)	MX25532A (2)
RU (1)	RU2100030C1 (2)
TW (1)	TW203559B (2)
WO (1)	WO1991016068A1 (2)
ZA (1)	ZA913122B (2)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6428529B1 (en)	1995-07-14	2002-08-06	Skyepharma Inc.	Epidural administration of therapeutic compounds with sustained rate of release
RU2208435C2 (ru) *	1998-04-14	2003-07-20	Астразенека Аб	Внедрение активных веществ в матрицы носителей
RU2235474C2 (ru) *	1999-07-16	2004-09-10	Унилевер Н.В.	Твердожировая масса, способ ее получения и применение
RU2239417C2 (ru) *	1999-01-18	2004-11-10	Грюненталь Гмбх	Опиоидные анальгетики с контролируемым высвобождением активных веществ
RU2292871C2 (ru) *	2001-10-19	2007-02-10	Айдекс Лэборэтериз, Инк.	Инъецируемые композиции для контролируемой доставки фармакологически активного соединения
RU2316315C2 (ru) *	2001-09-14	2008-02-10	Новартис Аг	Офтальмические композиции в форме депо для периокулярного или субконъюнктивального введения
RU2541156C1 (ru) *	2013-07-09	2015-02-10	Общество с ограниченной ответственностью Научно-производственное объединение "Клеточные технологии"	Трансдермальное антигельминтное средство на основе кремнийорганических ниосом с альбендазолом
RU2809143C2 (ru) *	2018-05-21	2023-12-07	Игл Фармасьютикалз, Инк.	Композиции дантролена и способы их применения

Families Citing this family (220)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5705187A (en) *	1989-12-22	1998-01-06	Imarx Pharmaceutical Corp.	Compositions of lipids and stabilizing materials
US5399363A (en) *	1991-01-25	1995-03-21	Eastman Kodak Company	Surface modified anticancer nanoparticles
AU642066B2 (en) *	1991-01-25	1993-10-07	Nanosystems L.L.C.	X-ray contrast compositions useful in medical imaging
US5552160A (en) *	1991-01-25	1996-09-03	Nanosystems L.L.C.	Surface modified NSAID nanoparticles
WO1993015731A1 (en) *	1992-02-14	1993-08-19	Robert Lamb	Phosphate derivatives of vitamin e to protect cells from effects of aging and injury
DE4221268C2 (de) *	1992-06-26	1997-06-12	Lancaster Group Ag	Verwendung eines Dermatikums zur Unterstützung des Sauerstofftransportes in der Haut
US5464696A (en) *	1992-08-13	1995-11-07	Bracco International B.V.	Particles for NMR imaging
US5336507A (en) *	1992-12-11	1994-08-09	Sterling Winthrop Inc.	Use of charged phospholipids to reduce nanoparticle aggregation
US20030073642A1 (en) *	1993-02-22	2003-04-17	American Bioscience, Inc.	Methods and formulations for delivery of pharmacologically active agents
US20070117862A1 (en) *	1993-02-22	2007-05-24	Desai Neil P	Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
FR2702160B1 (fr) *	1993-03-02	1995-06-02	Biovecteurs As	Vecteurs particulaires synthétiques et procédé de préparation.
DE19609538A1 (de) *	1996-03-11	1997-09-18	Basf Ag	Feinverteilte Carotinoid- und Retinoidsuspensionen und Verfahren zu ihrer Herstellung
DE4322158C2 (de) *	1993-07-03	1997-04-10	Rhone Poulenc Rorer Gmbh	Phospholipidische Zusammensetzung sowie Verwendung einer derartigen Zusammensetzung
US5393461A (en) *	1993-10-04	1995-02-28	Rtd Corporation	Preparation of stable aqueous emulsions of water-insoluble particles
JP4484247B2 (ja) *	1995-02-24	2010-06-16	エランファーマインターナショナル，リミティド	ナノ粒子分散体を含有するエアロゾル
US5747001A (en) *	1995-02-24	1998-05-05	Nanosystems, L.L.C.	Aerosols containing beclomethazone nanoparticle dispersions
DE19511276C2 (de) *	1995-03-27	1999-02-18	Immuno Ag	Adjuvans auf der Basis kolloidaler Eisenverbindungen
US5788959A (en)	1995-04-24	1998-08-04	University Of Maryland, Baltimore County	Drug delivery device and method for employing the same
US5785975A (en) *	1995-06-26	1998-07-28	Research Triangle Pharmaceuticals	Adjuvant compositions and vaccine formulations comprising same
US5834025A (en)	1995-09-29	1998-11-10	Nanosystems L.L.C.	Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
ATE386506T1 (de)	1995-10-17	2008-03-15	Jagotec Ag	Verabreichung unlöslicher arzneistoffe
US7255877B2 (en) *	1996-08-22	2007-08-14	Jagotec Ag	Fenofibrate microparticles
WO1998007414A1 (en)	1996-08-22	1998-02-26	Research Triangle Pharmaceuticals Ltd.	Compositions comprising microparticles of water-insoluble substances and method for preparing same
US6465016B2 (en)	1996-08-22	2002-10-15	Research Triangle Pharmaceuticals	Cyclosporiine particles
US8137684B2 (en)	1996-10-01	2012-03-20	Abraxis Bioscience, Llc	Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20070185032A1 (en) *	1996-12-11	2007-08-09	Praecis Pharmaceuticals, Inc.	Pharmaceutical formulations for sustained drug delivery
JP4642946B2 (ja)	1996-12-20	2011-03-02	アルザコーポレイション	ゲル組成物および方法
FR2757768B1 (fr) *	1996-12-27	1999-04-02	Biovector Therapeutics Sa	Vecteur particulaire homeocharge et composition pharmaceutique ou cosmetique le contenant
KR20000075745A (ko) *	1997-02-27	2000-12-26	가마후라 아키오	의약 조성물
WO1998047492A1 (en) *	1997-04-18	1998-10-29	Vertex Pharmaceuticals Incorporated	Nanosized aspartyl protease inhibitors
PT1023050E (pt) *	1997-06-27	2013-12-04	Abraxis Bioscience Llc	Novas formulações de agentes farmacológicos, métodos para a sua preparação e métodos para a sua utilização
US20030199425A1 (en) *	1997-06-27	2003-10-23	Desai Neil P.	Compositions and methods for treatment of hyperplasia
US6565885B1 (en) *	1997-09-29	2003-05-20	Inhale Therapeutic Systems, Inc.	Methods of spray drying pharmaceutical compositions
US20060165606A1 (en) *	1997-09-29	2006-07-27	Nektar Therapeutics	Pulmonary delivery particles comprising water insoluble or crystalline active agents
CA2312900A1 (en) *	1997-12-02	1999-06-10	Powderject Vaccines, Inc.	Transdermal delivery of particulate vaccine compositions
US20010003580A1 (en) *	1998-01-14	2001-06-14	Poh K. Hui	Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
DE69908304T2 (de) *	1998-02-11	2004-02-19	Rtp Pharma Corp.	Ungesättigte fettsäure und steroide enthaltende kombinationspräparate zur behandlung von entzündungen
US6979456B1 (en)	1998-04-01	2005-12-27	Jagotec Ag	Anticancer compositions
KR100635456B1 (ko)	1998-05-29	2006-10-18	스키에파마 캐나다 인코포레이티드	열보호화 마이크로입자 조성물 및 그의 말단의 스팀멸균방법
GB9814507D0 (en) *	1998-07-03	1998-09-02	Univ Southampton	A method and apparatus for controlling pests
US7343710B2 (en) *	1998-07-03	2008-03-18	I.D.A Limited	Method and apparatus for controlling pests
DE69912441T2 (de)	1998-08-19	2004-08-19	Skyepharma Canada Inc., Verdun	Injizierbare wässerige propofoldispersionen
NZ511798A (en) *	1998-10-19	2004-01-30	Powderject Vaccines Inc	Minimal promoters comprising a promoter not linked to its native enhancer and such minimal promoters linked to an antigen
US6881723B1 (en)	1998-11-05	2005-04-19	Powderject Vaccines, Inc.	Nucleic acid constructs
US6180136B1 (en)	1998-11-10	2001-01-30	Idexx Laboratories, Inc.	Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use
US7521068B2 (en) *	1998-11-12	2009-04-21	Elan Pharma International Ltd.	Dry powder aerosols of nanoparticulate drugs
US20040141925A1 (en) *	1998-11-12	2004-07-22	Elan Pharma International Ltd.	Novel triamcinolone compositions
IL143197A0 (en) *	1998-11-20	2002-04-21	Rtp Pharma Inc	Dispersible phospholipid stabilized microparticles
US6251886B1 (en)	1998-12-07	2001-06-26	Schering Corporation	Methods of using temozolomide in the treatment of cancers
US6682758B1 (en)	1998-12-22	2004-01-27	The United States Of America As Represented By The Department Of Health And Human Services	Water-insoluble drug delivery system
KR100359252B1 (ko) *	1999-12-21	2002-11-04	주식회사 엘지생명과학	항원을 포함하는 고체상 미세입자 및 이를 포함하는 제제
AU3593200A (en)	1999-02-09	2000-08-29	Powderject Vaccines, Inc.	(mycobacterium tuberculosis), immunization
WO2000050009A1 (en) *	1999-02-26	2000-08-31	Idexx Laboratories, Inc.	Methods for administering pharmacologically active compounds to vertebrates
US6248363B1 (en) *	1999-11-23	2001-06-19	Lipocine, Inc.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7374779B2 (en) *	1999-02-26	2008-05-20	Lipocine, Inc.	Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6602719B1 (en)	1999-03-26	2003-08-05	Idexx Laboratories, Inc.	Method and device for detecting analytes in fluids
US6551842B1 (en)	1999-03-26	2003-04-22	Idexx Laboratories, Inc.	Method and device for detecting analytes in fluids
US6511814B1 (en)	1999-03-26	2003-01-28	Idexx Laboratories, Inc.	Method and device for detecting analytes in fluids
US20030236236A1 (en) *	1999-06-30	2003-12-25	Feng-Jing Chen	Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
IL148247A0 (en)	1999-08-24	2002-09-12	Teva Pharma	A vaccine composition and method of using the same
US6592869B2 (en) *	1999-08-24	2003-07-15	Teva Pharmaceutical Industries, Ltd.	Vaccine composition and method of using the same
AU7984200A (en) *	1999-09-21	2001-04-24	Skyepharma Canada Inc.	Surface modified particulate compositions of biologically active substances
US6919009B2 (en) *	1999-10-01	2005-07-19	Nanoplex Technologies, Inc.	Method of manufacture of colloidal rod particles as nanobarcodes
US7225082B1 (en)	1999-10-01	2007-05-29	Oxonica, Inc.	Colloidal rod particles as nanobar codes
US20050032226A1 (en) *	1999-10-01	2005-02-10	Natan Michael J.	Encoded nanoparticles in paper manufacture
US20040209376A1 (en) *	1999-10-01	2004-10-21	Surromed, Inc.	Assemblies of differentiable segmented particles
US7045049B1 (en)	1999-10-01	2006-05-16	Nanoplex Technologies, Inc.	Method of manufacture of colloidal rod particles as nanobar codes
US20040178076A1 (en) *	1999-10-01	2004-09-16	Stonas Walter J.	Method of manufacture of colloidal rod particles as nanobarcodes
US7196066B1 (en)	1999-11-03	2007-03-27	Powderject Vaccines, Inc.	DNA-vaccines based on constructs derived from the genomes of human and animal pathogens
US7732404B2 (en)	1999-12-30	2010-06-08	Dexcel Ltd	Pro-nanodispersion for the delivery of cyclosporin
GB0009773D0 (en) *	2000-04-19	2000-06-07	Univ Cardiff	Particulate composition
EP1276465B1 (en)	2000-04-20	2014-03-12	Jagotec AG	Improved water-insoluble drug particle process
JP4763957B2 (ja)	2000-05-10	2011-08-31	オバン・エナジー・リミテッド	メディアミリング
EP1292282A2 (en)	2000-06-16	2003-03-19	RTP Pharma Inc.	Improved injectable dispersions of propofol
JP4969761B2 (ja)	2000-08-31	2012-07-04	オバン・エナジー・リミテッド	所望粒度を持つ固体基材の小粒子および第一材料の小粒状物を含む相乗作用性混合物を製造する方法
US6579519B2 (en) *	2000-09-18	2003-06-17	Registrar, University Of Delhi	Sustained release and long residing ophthalmic formulation and the process of preparing the same
EP1320362B1 (en) *	2000-09-20	2011-08-31	Jagotec AG	Stabilised fibrate microparticles
US8586094B2 (en) *	2000-09-20	2013-11-19	Jagotec Ag	Coated tablets
US20040077604A1 (en)	2001-12-19	2004-04-22	Lenard Lichtenberger	Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providingenhanced therapeutic activity
US20100173876A1 (en) *	2000-12-19	2010-07-08	The Board Of Regents Of The University Of Texas System	Oil-based nsaid compositions and methods for making and using same
CA2431606C (en) *	2000-12-19	2011-07-19	The Board Of Regents Of The University Of Texas System	Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providing enhanced therapeutic activity
US20040256749A1 (en) *	2000-12-22	2004-12-23	Mahesh Chaubal	Process for production of essentially solvent-free small particles
US20040022862A1 (en) *	2000-12-22	2004-02-05	Kipp James E.	Method for preparing small particles
US6951656B2 (en) *	2000-12-22	2005-10-04	Baxter International Inc.	Microprecipitation method for preparing submicron suspensions
US20030096013A1 (en) *	2000-12-22	2003-05-22	Jane Werling	Preparation of submicron sized particles with polymorph control
US8067032B2 (en) *	2000-12-22	2011-11-29	Baxter International Inc.	Method for preparing submicron particles of antineoplastic agents
US20050048126A1 (en) *	2000-12-22	2005-03-03	Barrett Rabinow	Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US6977085B2 (en) *	2000-12-22	2005-12-20	Baxter International Inc.	Method for preparing submicron suspensions with polymorph control
US9700866B2 (en) *	2000-12-22	2017-07-11	Baxter International Inc.	Surfactant systems for delivery of organic compounds
US7037528B2 (en) *	2000-12-22	2006-05-02	Baxter International Inc.	Microprecipitation method for preparing submicron suspensions
US20030072807A1 (en) *	2000-12-22	2003-04-17	Wong Joseph Chung-Tak	Solid particulate antifungal compositions for pharmaceutical use
US7193084B2 (en) *	2000-12-22	2007-03-20	Baxter International Inc.	Polymorphic form of itraconazole
US6884436B2 (en) *	2000-12-22	2005-04-26	Baxter International Inc.	Method for preparing submicron particle suspensions
US20020150615A1 (en) *	2001-02-12	2002-10-17	Howard Sands	Injectable pharmaceutical composition comprising microdroplets of a camptothecin
US6497896B2 (en)	2001-02-12	2002-12-24	Supergen, Inc.	Method for administering camptothecins via injection of a pharmaceutical composition comprising microdroplets containing a camptothecin
US6509027B2 (en)	2001-02-12	2003-01-21	Supergen, Inc.	Injectable pharmaceutical composition comprising coated particles of camptothecin
NZ527408A (en) *	2001-02-22	2005-04-29	Skyepharma Canada Inc	Hydroxymethylglutarylcoenzyme A (HMG CoA) reductase inhibitor (or a statin) and a fibrate in a single effective oral dosage form to treat dyslipidaemia and dyslipoproteinaemia
US20020176841A1 (en) *	2001-03-19	2002-11-28	Praecis Pharmaceuticals Inc.	Pharmaceutical formulations for sustained release
ATE440593T1 (de) *	2001-03-27	2009-09-15	Phares Pharm Res Nv	Verfahren und zusammensetzung zur solubilisierung einer biologisch wirksamen verbindung mit geringer wasserlíslichkeit
AU2002307090A1 (en) *	2001-04-03	2002-10-21	Surromed, Inc.	Methods and reagents for multiplexed analyte capture, surface array self-assembly, and analysis of complex biological samples
EP1392245A2 (en) *	2001-04-05	2004-03-03	Universite Laval	Process for making protein delivery matrix and uses thereof
GB0114532D0 (en) *	2001-06-14	2001-08-08	Jagotec Ag	Novel compositions
US6676958B2 (en) *	2001-06-19	2004-01-13	Advanced Bioadjuvants, Llc	Adjuvant composition for mucosal and injection delivered vaccines
US7758890B2 (en)	2001-06-23	2010-07-20	Lyotropic Therapeutics, Inc.	Treatment using dantrolene
GB0119480D0 (en) *	2001-08-09	2001-10-03	Jagotec Ag	Novel compositions
US20030054042A1 (en) *	2001-09-14	2003-03-20	Elaine Liversidge	Stabilization of chemical compounds using nanoparticulate formulations
US20060003012A9 (en) *	2001-09-26	2006-01-05	Sean Brynjelsen	Preparation of submicron solid particle suspensions by sonication of multiphase systems
BR0212833A (pt) *	2001-09-26	2004-10-13	Baxter Int	Preparação de nanopartìculas de tamanho submìcron através de dispersão e de remoção de solvente ou de fase lìquida
US7112340B2 (en) *	2001-10-19	2006-09-26	Baxter International Inc.	Compositions of and method for preparing stable particles in a frozen aqueous matrix
US20030129242A1 (en) *	2002-01-04	2003-07-10	Bosch H. William	Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
KR100836035B1 (ko) *	2002-02-19	2008-06-09	(주)아모레퍼시픽	포화 및 불포화 레시틴 함유 나노에멀젼 및 이를 함유하는화장료 조성물
WO2003080027A1 (en) *	2002-03-20	2003-10-02	Elan Pharma International, Ltd.	Nanoparticulate compositions of angiogenesis inhibitors
US20080220075A1 (en) *	2002-03-20	2008-09-11	Elan Pharma International Ltd.	Nanoparticulate compositions of angiogenesis inhibitors
US7101566B2 (en) *	2002-06-28	2006-09-05	Ethicon, Inc.	Polymer coated microparticles for sustained release
US20050169979A1 (en) *	2002-07-03	2005-08-04	Dov Michaeli	Liposomal vaccine
US20040247661A1 (en) *	2002-07-03	2004-12-09	Dov Michaeli	Liposomal vaccine
US7838034B2 (en) *	2002-07-30	2010-11-23	Grunenthal Gmbh	Intravenous pharmaceutical form of administration
WO2004035537A2 (en)	2002-10-16	2004-04-29	Euro-Celtique S.A.	Antibodies that bind cell-associated ca 125/o772p and methods of use thereof
RU2331424C2 (ru) *	2002-12-13	2008-08-20	Джеготек Аг	Топический состав, содержащий наночастицы спиронолактона
JP2006511525A (ja) *	2002-12-13	2006-04-06	ヤゴテックアーゲー	ナノ粒子状スピロノラクトン局所製剤
US7731947B2 (en) *	2003-11-17	2010-06-08	Intarcia Therapeutics, Inc.	Composition and dosage form comprising an interferon particle formulation and suspending vehicle
WO2005013919A2 (en)	2003-03-04	2005-02-17	Lyotropic Therapeutics, Inc.	Treatment using dantrolene
US20050019556A1 (en) *	2003-06-17	2005-01-27	Surromed, Inc.	Labeling and authentication of metal objects
DE10327839A1 (de) *	2003-06-20	2005-01-05	Arvinmeritor Gmbh	Fahrzeugdachmodul
US8986736B2 (en) *	2003-06-24	2015-03-24	Baxter International Inc.	Method for delivering particulate drugs to tissues
AU2004249172A1 (en) *	2003-06-24	2004-12-29	Baxter International Inc.	Specific delivery of drugs to the brain
US20080051373A1 (en) *	2003-07-31	2008-02-28	The Board Of Regents Of The University Of Texas System	Parenteral preparations of GI-safer phospholipid-associated anti-inflammatories and methods of preparation and use
US20050049209A1 (en) *	2003-08-06	2005-03-03	Chen Andrew Xian	Pharmaceutical compositions for delivering macrolides
JP2005097295A (ja) *	2003-09-01	2005-04-14	Wakunaga Pharmaceut Co Ltd	ビタミン安定液剤
AU2004275764B2 (en)	2003-09-22	2010-01-14	Baxter Healthcare S.A.	High-pressure sterilization to terminally sterilize pharmaceutical preparations and medical products
US20060003002A1 (en) *	2003-11-03	2006-01-05	Lipocine, Inc.	Pharmaceutical compositions with synchronized solubilizer release
JP3903061B2 (ja) *	2003-12-24	2007-04-11	株式会社Ｌｔｔバイオファーマ	薬物を含有するナノ粒子およびその製造方法、ならびに当該ナノ粒子からなる非経口投与用製剤
US20050202094A1 (en) *	2004-01-29	2005-09-15	Werling Jane O.	Nanosuspensions of anti-retroviral agents for increased central nervous system delivery
JP2007520555A (ja) *	2004-02-05	2007-07-26	バクスター・インターナショナル・インコーポレイテッド	自己安定化剤の使用により調製された分散剤
EP1730516A1 (en) *	2004-03-30	2006-12-13	Pfizer Products Incorporated	Method and device for evaluation of pharmaceutical compositions
US20060009469A1 (en) *	2004-05-28	2006-01-12	Leonore Witchey-Lakshmanan	Particulate-stabilized injectable pharmacutical compositions of posaconazole
CN1988887A (zh) *	2004-05-28	2007-06-27	先灵公司	包含泊沙康唑的注射用药物混悬剂
US20060160823A1 (en) *	2004-05-28	2006-07-20	Leonore Witchey-Lakshmanan	Particulate-stabilized injectable pharmaceutical compositions of Posaconazole
RU2006144851A (ru) *	2004-06-15	2008-06-20	Бакстер Интернэшнл Инк. (Us)	Применение терапевтических средств ex-vivo в виде твердых микрочастиц
US20080171687A1 (en) *	2004-09-16	2008-07-17	Abraxis Bioscience, Inc.	Compositions And Methods For The Preparation And Administration Of Poorly Water Soluble Drugs
US11246913B2 (en)	2005-02-03	2022-02-15	Intarcia Therapeutics, Inc.	Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en)	2005-02-03	2006-08-10	Alza Corporation	Solvent/polymer solutions as suspension vehicles
WO2006138202A2 (en) *	2005-06-14	2006-12-28	Baxter International Inc.	Pharmaceutical formulations for minimizing drug-drug interactions
US20070134341A1 (en) *	2005-11-15	2007-06-14	Kipp James E	Compositions of lipoxygenase inhibitors
AU2007233155B2 (en)	2006-03-29	2012-04-26	Scitech Development Llc	Liposomal nanoparticles and other formulations of fenretinide for use in therapy and drug delivery
WO2008054508A2 (en) *	2006-04-13	2008-05-08	Alza Corporation	Stable nanosized amorphous drug
KR101106510B1 (ko)	2006-05-30	2012-01-20	인타르시아 세라퓨틱스 인코포레이티드	투피스, 내부채널 삼투압 전달 시스템 유동 조절기
WO2008002485A2 (en) *	2006-06-23	2008-01-03	Alza Corporation	Increased amorphous stability of poorly water soluble drugs by nanosizing
ES2405733T3 (es) *	2006-07-26	2013-06-03	The Board Of Regents Of The University Of Texas System	Preparaciones parenterales de antiinflamatorios asociados a fosfolípidos GI más seguros y procedimientos de preparación y uso
EP2359808B1 (en)	2006-08-09	2013-05-22	Intarcia Therapeutics, Inc	Osmotic delivery systems and piston assemblies
AR063704A1 (es) *	2006-09-14	2009-02-11	Makhteshim Chem Works Ltd	Nanoparticulas de pesticida obtenida obtenidas a partir de microemulsiones y nanoemulsiones
EP2061583B1 (en) *	2006-09-14	2019-04-10	Yissum Research Development Company, of The Hebrew University of Jerusalem	Organic nanoparticles obtained from microemulsions by solvent evaporation
WO2008065502A1 (en) *	2006-11-29	2008-06-05	Pfizer Products Inc.	Pharmaceutical compositions based on a) nanoparticles comprising enteric polymers and b) casein
WO2008080047A2 (en) *	2006-12-23	2008-07-03	Baxter International Inc.	Magnetic separation of fine particles from compositions
WO2008125940A2 (en) *	2007-04-17	2008-10-23	Pfizer Products Inc.	Nanoparticles comprising non-crystalline drug
WO2008133908A2 (en)	2007-04-23	2008-11-06	Intarcia Therapeutics, Inc.	Suspension formulations of insulinotropic peptides and uses thereof
US8703204B2 (en) *	2007-05-03	2014-04-22	Bend Research, Inc.	Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
WO2008135852A2 (en) *	2007-05-03	2008-11-13	Pfizer Products Inc.	Pharmaceutical compositions comprising nanoparticles and casein
US8309129B2 (en) *	2007-05-03	2012-11-13	Bend Research, Inc.	Nanoparticles comprising a drug, ethylcellulose, and a bile salt
US8530463B2 (en) *	2007-05-07	2013-09-10	Hale Biopharma Ventures Llc	Multimodal particulate formulations
EP2152274A4 (en) *	2007-05-07	2010-07-21	Questor Pharmaceuticals Inc	NASAL ADMINISTRATION OF BENZODIAZEPINES
US8426467B2 (en) *	2007-05-22	2013-04-23	Baxter International Inc.	Colored esmolol concentrate
US20080292663A1 (en) *	2007-05-22	2008-11-27	Gerber Jay D	Adjuvant compositions and methods for delivering vaccines
US8722736B2 (en) *	2007-05-22	2014-05-13	Baxter International Inc.	Multi-dose concentrate esmolol with benzyl alcohol
US20080293814A1 (en) *	2007-05-22	2008-11-27	Deepak Tiwari	Concentrate esmolol
WO2008149230A2 (en)	2007-06-04	2008-12-11	Pfizer Products Inc.	Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
EP2162120B1 (en) *	2007-06-04	2016-05-04	Bend Research, Inc	Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
US20080319039A1 (en) *	2007-06-25	2008-12-25	Jacqueline Rose Bersch	Unit dosage forms of temozolomide
US20100215747A1 (en) *	2007-07-13	2010-08-26	Corey Jay Bloom	Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
CN106310293A (zh)	2007-09-27	2017-01-11	免疫疫苗技术有限公司	在包括连续疏水相的载体中的脂质体在体内输送多核苷酸中的应用
WO2009073216A1 (en) *	2007-12-06	2009-06-11	Bend Research, Inc.	Nanoparticles comprising a non-ionizable polymer and an amine-functionalized methacrylate copolymer
EP2231169B1 (en) *	2007-12-06	2016-05-04	Bend Research, Inc.	Pharmaceutical compositions comprising nanoparticles and a resuspending material
EP2244783B1 (en)	2008-01-22	2019-12-18	Board Of Regents, The University Of Texas System	Volatile anesthetic compositions and methods of use
CA2726861C (en)	2008-02-13	2014-05-27	Intarcia Therapeutics, Inc.	Devices, formulations, and methods for delivery of multiple beneficial agents
RU2496482C2 (ru)	2008-03-05	2013-10-27	Бакстер Интернэшнл Инк.	Композиции и способы для доставки лекарственных средств
CA2718416C (en) *	2008-03-13	2018-01-02	Mallinckrodt Inc.	Multi-function, foot-activated controller for imaging system
US20090258865A1 (en)	2008-03-28	2009-10-15	Hale Biopharma Ventures, Llc	Administration of benzodiazepine compositions
WO2009146523A1 (en)	2008-06-05	2009-12-10	Immunovaccine Technologies Inc.	Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
US8173621B2 (en)	2008-06-11	2012-05-08	Gilead Pharmasset Llc	Nucleoside cyclicphosphates
GB2460915B (en) *	2008-06-16	2011-05-25	Biovascular Inc	Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
PA8855601A1 (es)	2008-12-23	2010-07-27		Forformidatos de nucleósidos
AU2009329872B2 (en)	2008-12-23	2016-07-07	Gilead Pharmasset Llc	Synthesis of purine nucleosides
NZ593649A (en)	2008-12-23	2013-11-29	Gilead Pharmasset Llc	Nucleoside analogs
US11304960B2 (en)	2009-01-08	2022-04-19	Chandrashekar Giliyar	Steroidal compositions
CN109394689A (zh) *	2009-05-05	2019-03-01	德州大学系统董事会	挥发性麻醉剂的新型制剂及其用于减轻炎症的使用方法
US10952965B2 (en) *	2009-05-15	2021-03-23	Baxter International Inc.	Compositions and methods for drug delivery
TWI583692B (zh)	2009-05-20	2017-05-21	基利法瑪席特有限責任公司	核苷磷醯胺
RU2547990C2 (ru)	2009-09-28	2015-04-10	Интарсия Терапьютикс, Инк.	Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
UY33310A (es)	2010-03-31	2011-10-31	Pharmasset Inc	Sintesis estereoselectiva de activos que contienen fosforo
SG184324A1 (en)	2010-03-31	2012-11-29	Gilead Pharmasset Llc	Nucleoside phosphoramidates
US8563530B2 (en)	2010-03-31	2013-10-22	Gilead Pharmassel LLC	Purine nucleoside phosphoramidate
US9034858B2 (en)	2010-11-30	2015-05-19	Lipocine Inc.	High-strength testosterone undecanoate compositions
US20180153904A1 (en)	2010-11-30	2018-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US9358241B2 (en)	2010-11-30	2016-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
CA2818853A1 (en)	2010-11-30	2012-06-07	Gilead Pharmasset Llc	2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
US20120310140A1 (en)	2010-12-01	2012-12-06	Spinal Modulation, Inc.	Directed delivery of agents to neural anatomy
US20120148675A1 (en)	2010-12-10	2012-06-14	Basawaraj Chickmath	Testosterone undecanoate compositions
US20120208755A1 (en)	2011-02-16	2012-08-16	Intarcia Therapeutics, Inc.	Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
ES2683902T3 (es)	2011-06-14	2018-09-28	Hale Biopharma Ventures, Llc	Administración de benzodiacepina
EP2760433B1 (en)	2011-09-29	2023-05-31	PLx Opco Inc.	pH DEPENDENT CARRIERS FOR TARGETED RELEASE OF PHARMACEUTICALS ALONG THE GASTROINTESTINAL TRACT, COMPOSITIONS THEREFROM, AND MAKING AND USING SAME
CN113876945A (zh)	2011-10-06	2022-01-04	免疫疫苗技术有限公司	包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用
EP4218808A3 (en)	2012-03-12	2023-08-09	Advanced BioAdjuvants, LLC	Adjuvant and vaccine compositions
PL2968214T3 (pl)	2013-03-15	2021-11-02	Newvapogen, Inc.	Nowe kompozycje przeciwbólowe
US9498485B2 (en)	2014-08-28	2016-11-22	Lipocine Inc.	Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
WO2016033549A2 (en)	2014-08-28	2016-03-03	Lipocine Inc.	(17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9889085B1 (en)	2014-09-30	2018-02-13	Intarcia Therapeutics, Inc.	Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
RU2730996C2 (ru)	2015-06-03	2020-08-26	Интарсия Терапьютикс, Инк.	Системы установки и извлечения имплантата
US20160361322A1 (en)	2015-06-15	2016-12-15	Lipocine Inc.	Composition and method for oral delivery of androgen prodrugs
WO2017097855A1 (en) *	2015-12-08	2017-06-15	Verano Ilac Sanayi Ticaret Anonim Sirketi	An injectable composition of ricobendazole
KR102574993B1 (ko)	2016-05-16	2023-09-06	인타르시아 세라퓨틱스 인코포레이티드	글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD840030S1 (en)	2016-06-02	2019-02-05	Intarcia Therapeutics, Inc.	Implant placement guide
USD860451S1 (en)	2016-06-02	2019-09-17	Intarcia Therapeutics, Inc.	Implant removal tool
US11559530B2 (en)	2016-11-28	2023-01-24	Lipocine Inc.	Oral testosterone undecanoate therapy
JP7286542B2 (ja)	2017-01-03	2023-06-05	インターシアセラピューティクス，インコーポレイティド	Ｇｌｐ－１受容体アゴニストの持続的投与及び薬物の同時投与を含む方法
US12599562B2 (en) *	2017-11-09	2026-04-14	The Board Of Regents Of The University Of Oklahoma	Nanocrystal microparticles of poorly soluble drugs and methods of production and use thereof
WO2020018974A1 (en)	2018-07-20	2020-01-23	Lipocine Inc.	Liver disease
JP2023518822A (ja)	2020-03-26	2023-05-08	ピーエルエックスオプコインコーポレイテッド	ｐＨ依存的再構築が可能な医薬キャリア、その製造方法及び使用方法
US11992483B2 (en)	2021-03-31	2024-05-28	Cali Biosciences Us, Llc	Emulsions for local anesthetics
JP2024521399A (ja)	2021-06-10	2024-05-31	ニューレリス、インク．	小児患者における発作性障害を治療するための組成物および方法
CN116687847B (zh) *	2023-06-26	2024-03-29	石家庄四药有限公司	一种药物微晶注射液及其制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1502774A (en) *	1974-06-25	1978-03-01	Nat Res Dev	Immunological preparations
GB1578776A (en) *	1976-06-10	1980-11-12	Univ Illinois	Hemoglobin liposome and method of making the same
US4078052A (en) *	1976-06-30	1978-03-07	The United States Of America As Represented By The Secretary Of Health, Education And Welfare	Large unilamellar vesicles (LUV) and method of preparing same
US4298594A (en) *	1978-04-14	1981-11-03	Arthur D. Little, Inc.	Xenobiotic delivery vehicles, method of forming them and method of using them
DE2856333C2 (de) *	1978-12-27	1983-09-22	A. Nattermann & Cie GmbH, 5000 Köln	Oral einnehmbare Arzneimittel mit entzündungshemmender Wirkung
US4378354A (en) *	1978-12-27	1983-03-29	A. Nattermann & Cie. Gmbh	Inflammation-preventing pharmaceutical composition of oral administration
US4421747A (en) *	1978-12-27	1983-12-20	A. Nattermann & Cie. Gmbh	Inflammation-preventing pharmaceutical composition of oral administration
DE2914788A1 (de) *	1979-04-11	1980-10-16	Nattermann A & Cie	Parenteral applizierbare, stabile arzneimittelloesungen mit entzuendungshemmender wirkung
US4345588A (en) *	1979-04-23	1982-08-24	Northwestern University	Method of delivering a therapeutic agent to a target capillary bed
JPS562353A (en) *	1979-06-20	1981-01-12	Ricoh Co Ltd	Novel disazo compound and its preparation
CA1173360A (en) *	1979-06-22	1984-08-28	Jurg Schrank	Pharmaceutical preparations
AR220263A1 (es) *	1980-02-19	1980-10-15	Bago Lab Sa	Procedimiento para obtener una preparacion inyectable de sulfonamida potenciada de baja irritabilidad
US4331654A (en) *	1980-06-13	1982-05-25	Eli Lilly And Company	Magnetically-localizable, biodegradable lipid microspheres
US5030453A (en) *	1983-03-24	1991-07-09	The Liposome Company, Inc.	Stable plurilamellar vesicles
US4515736A (en) *	1983-05-12	1985-05-07	The Regents Of The University Of California	Method for encapsulating materials into liposomes
US4725442A (en) *	1983-06-17	1988-02-16	Haynes Duncan H	Microdroplets of water-insoluble drugs and injectable formulations containing same
US4622219A (en) *	1983-06-17	1986-11-11	Haynes Duncan H	Method of inducing local anesthesia using microdroplets of a general anesthetic
US4492720A (en) *	1983-11-15	1985-01-08	Benjamin Mosier	Method of preparing microspheres for intravascular delivery
US4610868A (en) *	1984-03-20	1986-09-09	The Liposome Company, Inc.	Lipid matrix carriers for use in drug delivery systems
JPS60208910A (ja) *	1984-03-31	1985-10-21	Green Cross Corp:The	水難溶性薬物・リン脂質複合体の製造方法
JPS6176414A (ja) *	1984-09-21	1986-04-18	Shionogi & Co Ltd	リポソーム製剤の製法
US4761288A (en) *	1984-09-24	1988-08-02	Mezei Associates Limited	Multiphase liposomal drug delivery system
JPH0688911B2 (ja) *	1985-06-06	1994-11-09	国立予防衛生研究所長	インフルエンザワクチン及びその製造方法
JPH0617309B2 (ja) *	1985-11-29	1994-03-09	株式会社ビタミン研究所	アドリアマイシン包埋リポソ−ム製剤
AU7128887A (en) *	1986-02-10	1987-08-25	Liposome Technology, Inc.	Controlled-release liposome delivery system
US4803070A (en) *	1986-04-15	1989-02-07	Ribi Immunochem Research Inc.	Immunological emulsion adjuvants for polysaccharide vaccines
US4806352A (en) *	1986-04-15	1989-02-21	Ribi Immunochem Research Inc.	Immunological lipid emulsion adjuvant
US4806350A (en) *	1986-04-18	1989-02-21	Norden Laboratories, Inc.	Vaccine formulation
JPS62278241A (ja) *	1986-05-26	1987-12-03	Shoei Kagaku Kogyo Kk	ボンデイングワイヤ
US4776991A (en) *	1986-08-29	1988-10-11	The United States Of America As Represented By The Secretary Of The Navy	Scaled-up production of liposome-encapsulated hemoglobin
CA1338736C (fr) *	1986-12-05	1996-11-26	Roger Baurain	Microcristaux comportant une substance active presentant une affinite pour les phospholipides, et au moins un phospholipide, procede de preparation
DK175531B1 (da) *	1986-12-15	2004-11-22	Nexstar Pharmaceuticals Inc	Leveringsvehikel med amphiphil-associeret aktiv bestanddel
US4839111A (en) *	1987-02-02	1989-06-13	The University Of Tennessee Research Corporation	Preparation of solid core liposomes
FR2651680B1 (fr) *	1989-09-14	1991-12-27	Medgenix Group Sa	Nouveau procede de preparation de microparticules lipidiques.
GB8921222D0 (en) *	1989-09-20	1989-11-08	Riker Laboratories Inc	Medicinal aerosol formulations

1990
- 1990-04-26 US US07/514,012 patent/US5091188A/en not_active Expired - Lifetime
1991
- 1991-04-23 RU RU9292016352A patent/RU2100030C1/ru active
- 1991-04-23 DE DE69131349T patent/DE69131349T2/de not_active Expired - Lifetime
- 1991-04-23 JP JP50885491A patent/JP3261129B2/ja not_active Expired - Lifetime
- 1991-04-23 EP EP91908933A patent/EP0533690B1/en not_active Expired - Lifetime
- 1991-04-23 ES ES91908933T patent/ES2134776T3/es not_active Expired - Lifetime
- 1991-04-23 KR KR1019920702656A patent/KR0159114B1/ko not_active Expired - Lifetime
- 1991-04-23 WO PCT/US1991/002804 patent/WO1991016068A1/en not_active Ceased
- 1991-04-23 CA CA002078990A patent/CA2078990C/en not_active Expired - Lifetime
- 1991-04-23 AT AT91908933T patent/ATE181234T1/de not_active IP Right Cessation
- 1991-04-23 AU AU78528/91A patent/AU7852891A/en not_active Abandoned
- 1991-04-23 DK DK91908933T patent/DK0533690T3/da active
- 1991-04-25 ZA ZA913122A patent/ZA913122B/xx unknown
- 1991-04-26 MX MX2553291A patent/MX25532A/es unknown
- 1991-05-22 TW TW080103981A patent/TW203559B/zh not_active IP Right Cessation
1994
- 1994-09-12 US US08/304,225 patent/USRE35338E/en not_active Expired - Lifetime
1999
- 1999-07-20 GR GR990401915T patent/GR3030825T3/el unknown

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
US, патент, 4725442, кл. A 61 K 9/10, 1988. *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6428529B1 (en)	1995-07-14	2002-08-06	Skyepharma Inc.	Epidural administration of therapeutic compounds with sustained rate of release
RU2208435C2 (ru) *	1998-04-14	2003-07-20	Астразенека Аб	Внедрение активных веществ в матрицы носителей
RU2239417C2 (ru) *	1999-01-18	2004-11-10	Грюненталь Гмбх	Опиоидные анальгетики с контролируемым высвобождением активных веществ
RU2235474C2 (ru) *	1999-07-16	2004-09-10	Унилевер Н.В.	Твердожировая масса, способ ее получения и применение
RU2316315C2 (ru) *	2001-09-14	2008-02-10	Новартис Аг	Офтальмические композиции в форме депо для периокулярного или субконъюнктивального введения
RU2292871C2 (ru) *	2001-10-19	2007-02-10	Айдекс Лэборэтериз, Инк.	Инъецируемые композиции для контролируемой доставки фармакологически активного соединения
RU2541156C1 (ru) *	2013-07-09	2015-02-10	Общество с ограниченной ответственностью Научно-производственное объединение "Клеточные технологии"	Трансдермальное антигельминтное средство на основе кремнийорганических ниосом с альбендазолом
RU2809143C2 (ru) *	2018-05-21	2023-12-07	Игл Фармасьютикалз, Инк.	Композиции дантролена и способы их применения

Also Published As

Publication number	Publication date
DK0533690T3 (da)	1999-11-22
GR3030825T3 (en)	1999-11-30
US5091188A (en)	1992-02-25
JPH05507685A (ja)	1993-11-04
WO1991016068A1 (en)	1991-10-31
DE69131349D1 (de)	1999-07-22
TW203559B (2)	1993-04-11
ATE181234T1 (de)	1999-07-15
AU7852891A (en)	1991-11-11
CA2078990A1 (en)	1991-10-27
EP0533690B1 (en)	1999-06-16
DE69131349T2 (de)	1999-11-18
EP0533690A1 (en)	1993-03-31
ES2134776T3 (es)	1999-10-16
CA2078990C (en)	2002-06-04
JP3261129B2 (ja)	2002-02-25
USRE35338E (en)	1996-09-24
ZA913122B (en)	1992-04-29
KR0159114B1 (ko)	1998-12-01
MX25532A (es)	1993-10-01
EP0533690A4 (en)	1993-04-14

Publication	Publication Date	Title
RU2100030C1 (ru)	1997-12-27	Водная суспензия, содержащая микрокристаллы фармакологически активного водонерастворимого лекарственного вещества, покрытые мембранообразующим липидом (варианты), и лиофилизированный препарат водной суспензии
US5091187A (en)	1992-02-25	Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
JP2518605B2 (ja)	1996-07-24	水不溶性薬剤を含む微小滴
US5227165A (en)	1993-07-13	Liposphere delivery systems for local anesthetics
US5246707A (en)	1993-09-21	Sustained release delivery of water-soluble bio-molecules and drugs using phospholipid-coated microcrystals, microdroplets and high-concentration liposomes
KR100243921B1 (ko)	2000-03-02	규정된 지질계를 함유하는 제약조성물
ES2343767T3 (es)	2010-08-09	Composiciones anestesicas liposomicas de liberacion sostenida.
US5665379A (en)	1997-09-09	Lipid particle forming matrix, preparation and use thereof
HU213669B (en)	1997-09-29	Preparation suitable for local treatment and comprising suspension of solid lipid particles, as well as process for producing same and pharmaceutical compositions for local treatment of body
CA2069760C (en)	1998-02-10	Lipid formulation system
JP2007508311A (ja)	2007-04-05	逆液晶相材料に基づく薬物送達ビヒクル
NL8802657A (nl)	1989-05-16	Geneesmiddeldragers.
AU763945B2 (en)	2003-08-07	Oil-core compositions for the sustained release of hydrophobic drugs
DE69426570T2 (de)	2001-08-23	Mizelleförmige feinteilige pharmazeutische zusammensetzungen
JPH0798740B2 (ja)	1995-10-25	薬物担体
Lakshmi et al.	2020	Ufasomes: A potential vesicular carrier system
EP0521562A1 (en)	1993-01-07	Vesicles in non-polar media
CN101669904A (zh)	2010-03-17	一种依前列醇脂质纳米粒及制备方法
US20040213837A1 (en)	2004-10-28	Oil-core compositions for the sustained release of hydrophobic drugs
Jansen et al.	2001	Encapsulation to deliver topical actives
JP2911550B2 (ja)	1999-06-23	リポソーム製剤
JPH01501622A (ja)	1989-06-08	リポソームにカプセル包囲された非ステロイド性抗炎症薬を用いる方法および組成物
DAVIS et al.	1985	University of Nottingham, Nottingham, England
JPS63264517A (ja)	1988-11-01	医薬組成物
JPS62142111A (ja)	1987-06-25	組織標的型製剤組成物

Info

Links

Images

Classifications

Landscapes

Applications Claiming Priority (4)

Publications (2)

Family

ID=24045456

Family Applications (1)

Country Status (16)

Cited By (8)

Families Citing this family (220)

Family Cites Families (35)

Non-Patent Citations (1)

Cited By (8)

Also Published As

Similar Documents